Back

Similarities and differences between SGLT2i trials in HFpEF

24 May 2022 (08:30 - 08:45)
Organised by:
Congress Presentation Part of: What next for trials in heart failure with preserved ejection fraction? Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2022

About the speaker

Photo
Professor Scott Solomon

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

3 More presentations in this session

Presentation thumbnail
Do we need trials to account for sex differences in HFpEF?
Professor C. Lam (Singapore, SG)
Slides Video
Presentation thumbnail
Do we need trials of combination pharmacotherapy?
Professor N. Sato (Kawaguchi, JP)
Slides Video
Presentation thumbnail
What next for trials in heart failure with preserved ejection fraction? - discussion.
Video

Access the full session

Session thumbnail
What next for trials in heart failure with preserved ejection fraction?
Video

The Event

Event poster

Heart Failure 2022

24 May 2022 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Expanding evidence on SGLT2i: where are we now and what can we expect?
22 May 2022
thumbnail
Congress Presentation
SGLT2i is indicated for all HFpEF patients - pro.
23 May 2022
thumbnail
Congress Presentation
EMPEROR-Preserved: Outcomes using alternate endpoint definitions
23 May 2022
thumbnail
Congress Presentation
A Pre-Specified Meta-Analysis of DELIVER and EMPEROR-Preserved.
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources